Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.
Hardly for the first time recently, the company is making a pricey acquisition.
Hardly for the first time recently, the company is making a pricey acquisition.
BELLINGS Intelligence Score: 12
Why it matters
This acquisition is a routine corporate M&A transaction within the pharmaceutical sector and does not materially alter credit markets, underwriting standards, or systemic credit conditions.